RT Journal Article
T1 Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
A1 Pavel, Marianne
A1 Gross, David J
A1 Benavent, Marta
A1 Perros, Petros
A1 Srirajaskanthan, Raj
A1 Warner, Richard R P
A1 Kulke, Matthew H
A1 Anthony, Lowell B
A1 Kunz, Pamela L
A1 Hörsch, Dieter
A1 Weickert, Martin O
A1 Lapuerta, Pablo
A1 Jiang, Wenjun
A1 Kassler-Taub, Kenneth
A1 Wason, Suman
A1 Fleming, Rosanna
A1 Fleming, Douglas
A1 Garcia-Carbonero, Rocio
K1 5-HIAA
K1 carcinoid syndrome
K1 metastatic neuroendocrine tumor
K1 serotonin
K1 somatostatin analog
AB Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) with
YR 2018
FD 2018-01-12
LK http://hdl.handle.net/10668/12005
UL http://hdl.handle.net/10668/12005
LA en
DS RISalud
RD Apr 6, 2025